B
BenchSci
Generating searchable results to help shorten the drug discovery process
About BenchSci
BenchSci is a startup that operates in the biotechnology sector, specifically focusing on preclinical research and development (R&D). The company uses artificial intelligence (AI) and proprietary visual machine learning to create a comprehensive map of disease biology. This map is built using data from published experiments, internal data, vendor catalogs, and ontology datasets. The aim is to help scientists understand existing research, thereby increasing the efficiency and yield of their R&D efforts.
Read full description
BenchSci's primary product is ASCEND, a preclinical R&D platform. This platform uses patented machine learning technology to extract evidence from various data sources. It is designed to assist scientists across different therapeutic areas and at any stage of a research project. ASCEND helps in hypothesis generation, developing experimental approaches, and identifying risks from preclinical experiments.
The company's business model revolves around providing this platform to scientists and research organizations. By offering a tool that can augment due diligence, accelerate research, and reduce risks, BenchSci is able to generate revenue. The platform's intuitive interface and easy deployment across an enterprise make it a valuable tool for its clients.
In summary, BenchSci operates in the biotech market, serving scientists and research organizations. It uses AI and machine learning to extract and organize data, which is then used to assist in preclinical R&D. The company generates income by providing its ASCEND platform to clients.
At a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Toronto, Canada
- Employees
- 265
- Open positions
- 2
- Dealroom signal
- 62.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Core AI, Spinout, Tech for Biotech and Pharma, Generative AI, AI Drug Discovery, genAI Model Maker, genAI Applications, ai model layer, NIF defense security and resilience
- Business model
- Manufacturing
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | May 2023 | $70M | $279M | TCV · Inovia Capital · Golden Ventures · F-Prime | ↗ |
| SERIES COther financing | Jan 2022 | $46M | $185M | Northleaf · Golden Ventures · Inovia Capital · TCV | ↗ |
Growth signals
Latest recorded traffic for BenchSci is 19K monthly website visits, down 9.5% over the last three months. BenchSci's team declined 6.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed6 investors entered at this stage
Ontario Centre of Innovation
Two Small Fish Ventures
Real Ventures
Golden Venture Partners
Afore Capital
Radical Investments
Series A4 investors entered at this stage
Inovia Capital
Gradient Ventures
F-Prime
Northleaf
Series B and later3 investors entered at this stage
TCV
Golden Ventures
Generation Investment Management
Other known investors1 additional known investor
University of Toronto
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about BenchSci on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BenchSci’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.